Cardiovascular Drugs MGR 2017

Cardiovascular Drugs MGR 2017


  • Products Id :- TBRC2092
  • |
  • Pages: 125
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

This report will be delivered within 24 hours (excluding weekends) of the purchase.

Executive Summary

Cardiovascular disorders drug market covers the drugs used to treat conditions that affect heart or blood vessels. These conditions include heart stroke, coronary artery diseases, valvular diseases, peripheral venous diseases, pericarditis, endocarditis, cardiac tumors, arteriosclerosis, and lymphatic diseases. Some of the major cardiovascular drugs include anticoagulants such as Rivaroxaban (Xarelto), Dabigatran (Pradaxa), Apixaban (Eliquis), Heparin, and Warfarin.

The global cardiovascular disorders drugs market was estimated to be around $126 billion as of 2016. The cardiovascular disorders drugs market made up around 12% of the overall pharmaceuticals market in 2016. The cardiovascular disorders drugs market was the third largest market, following the pharmaceutical drugs and biologics market in the global pharmaceutical market in 2016.

Development Of Personalized Medicine For The Treatment Of Cardiovascular Diseases

Innovation of gene testing technologies for the development of personalized medicine for cardiovascular diseases is one of the major trend in the market. Due to the reduction in the cost of gene testing, patients can screen for their predisposition for specific cardiovascular diseases. Gene testing helps in development of personalized pharmacogenomic agents and improved patient monitoring efforts and detect them before an onset of acute care episodes.

The Cardiovascular Drugs Market Global Report provides strategists, marketers and senior management with the critical information they need to assess the global cardiovascular drugs sector.

Reasons to Purchase

Outperform competitors using accurate up to date demand-side dynamics information.

Identify growth segments for investment.

Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.

Create regional and country strategies on the basis of local data and analysis.

Stay abreast of the latest customer and market research findings

Benchmark performance against key competitors.

Develop strategies based on likely future developments.

Utilize the relationships between key data sets for superior strategizing.

Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Gain a global perspective on the development of the market.

Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Description:

Where is the largest and fastest growing market for the cardiovascular drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cardiovascular drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider pharmaceutical drugs market, and compares it with other markets.

The market characteristics section of the report defines and explains the market.

The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.

Market segmentations break down market into sub markets.

The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.

Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.

The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.

The Cardiovascular Drugs market section of the report gives context. It compares the cardiovascular drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast. It analyses Expenditure Per Capita, The Cardiovascular Drugs Indicators Comparison.

The industry metrics section looks at critical drivers including patient numbers (epidemiology) hospital beds and specialist physicians while the macro-economic section looks at the market in relation to the overall economy.

Scope

Markets Covered: Anti-Hypertensive, Hypolipidemics, Anti Thrombotics, Others (Congestive Heart Failure, Anti- Arrythmic And Anti-Anginal Drugs)

Companies Mentioned: Bristol-Myers Squibb Company, Abbott Laboratories Inc., AstraZeneca PLC, Bayer AG, and Novartis AG

Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.

Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa

Time series: Five years historic and forecast.

Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Cardiovascular Drugs Indicators Comparison.

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1. Cardiovascular Drugs Market Characteristics;

2. Cardiovascular Drugs Market Size And Growth;

2.1. Historic Market Growth; 2.1.1. Drivers Of The Market; 2.1.2. Restraints On The Market; 2.2. Forecast Market Growth; 2.2.1. Drivers Of The Market; 2.2.2. Restraints On The Market;

3. Pestle Analysis;

3.1. Political; 3.2. Economic; 3.3. Social; 3.4. Technological; 3.5. Legal; 3.6. Environmental;

4. Cardiovascular Drugs Market Customer Information;

5. Cardiovascular Drugs Market Segmentation;

5.1. Global Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 5.2. Global Cardiovascular Drugs Market, 2012-2020, Historic And Forecast, By Segment; 5.3 Global Cardiovascular Drugs Market Trends And Strategies;

6. Cardiovascular Drugs Market Regional And Country Analysis;

6.1. Global Cardiovascular Drugs Market, 2016, By Region; 6.2. Global Cardiovascular Drugs Market, 2012-2020, Historic And Forecast, By Region; 6.3. Cardiovascular Drugs Market, 2016, By Country; 6.4. Cardiovascular Drugs Market, 2012-2020, Historic And Forecast, By Country; 6.5. Global Pharmaceutical Market Segments, 2016, By Region; 6.6. Global Pharmaceutical Drugs Market Segments, 2016, By Region; 6.7. Global Pharmaceutical Market Segments, 2016, By Country; 6.8. Global Pharmaceutical Drugs Market Segments, 2016, By Country

7. Global Cardiovascular Drugs Market Comparison With Macro Economic Factors;

7.1. Cardiovascular Drugs Market Size, Percentage Of GDP, Global; 7.2. Per Capita Average Cardiovascular Drugs Expenditure, Global;

8. Cardiovascular Drugs Market Comparison With Macro Economic Factors Across Countries;

8.1. Cardiovascular Drugs Market Size, Percentage Of GDP, By Country; 8.2. Per Capita Average Cardiovascular Drugs Expenditure, By Country;

9. Cardiovascular Drugs Market Comparison With Industry Metrics;

9.1. Global Number Of Pharmacists, 2016, By Country; 9.2. Global Cardiovascular Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country; 9.3. Global Number Of Pharma Enterprises, 2016, By Country; 9.4. Global Cardiovascular Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country; 9.5. Global Average Spending On R&D/Product Development, 2016, By Country; 9.6. Global Cardiovascular Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country; 9.7. Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.8. Global Cardiovascular Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.9. Prevalent Cases Of Hypertension, 2014, By Country; 9.10. Prevalent Cases Of Parkinsons Disease, 2014, By Country; 9.11. Global Number Of General Practitioners 2016, By Country; 9.12. Global Cardiovascular Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country;

10. Asia-Pacific Cardiovascular Drugs Market;

10.1.1. Asia-Pacific Cardiovascular Drugs Market Overview; 10.1.2. Asia-Pacific Cardiovascular Drugs Historic Market, 2012-2016; 10.1.3. Asia-Pacific Cardiovascular Drugs Forecast Market, 2016-2020; 10.1.4. Asia-Pacific Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 10.2. Asia-Pacific Cardiovascular Drugs Market: Country Analysis; 10.3. China Cardiovascular Drugs Market; 10.3.1. China Cardiovascular Drugs Market Overview; 10.3.2. China Cardiovascular Drugs Historic Market, 2012-2016; 10.3.3. China Cardiovascular Drugs Forecast Market, 2016-2020; 10.3.4. China Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 10.3.5. China Cardiovascular Drugs Percentage Of GDP, 2012-2020; 10.3.6. China Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020; 10.4. India Cardiovascular Drugs Market; 10.4.1. India Cardiovascular Drugs Market Overview; 10.4.2. India Cardiovascular Drugs Historic Market, 2012-2016; 10.4.3. India Cardiovascular Drugs Forecast Market, 2016-2020; 10.4.4. India Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 10.4.5. India Cardiovascular Drugs Percentage Of GDP, 2012-2020; 10.4.6. India Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020; 10.5. Japan Cardiovascular Drugs Market; 10.5.1. Japan Cardiovascular Drugs Market Overview; 10.5.2. Japan Cardiovascular Drugs Historic Market, 2012-2016; 10.5.3. Japan Cardiovascular Drugs Forecast Market, 2016-2020; 10.5.4. Japan Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 10.5.5. Japan Cardiovascular Drugs Percentage Of GDP, 2012-2020; 10.5.6. Japan Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020; 10.6. Australia Cardiovascular Drugs Market; 10.6.1. Australia Cardiovascular Drugs Historic Market, 2012-2016; 10.6.2. Australia Cardiovascular Drugs Forecast Market, 2016-2020; 10.6.3. Australia Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 10.6.4. Australia Cardiovascular Drugs Percentage Of GDP, 2012-2020; 10.6.5. Australia Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020;

11. Western Europe Cardiovascular Drugs Market;

11.1.1. Western Europe Cardiovascular Drugs Market Overview; 11.1.2. Western Europe Cardiovascular Drugs Historic Market, 2012-2016; 11.1.3. Western Europe Cardiovascular Drugs Forecast Market, 2016-2020; 11.1.4. Western Europe Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 11.2. Western Europe Cardiovascular Drugs Market: Country Analysis; 11.3. UK Cardiovascular Drugs Market; 11.3.1. UK Cardiovascular Drugs Market Overview; 11.3.2. UK Cardiovascular Drugs Historic Market, 2012-2016; 11.3.3. UK Cardiovascular Drugs Forecast Market, 2016-2020; 11.3.4. UK Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 11.3.5. UK Cardiovascular Drugs Percentage Of GDP, 2012-2020; 11.3.6. UK Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020; 11.4. Germany Cardiovascular Drugs Market; 11.4.1. Germany Cardiovascular Drugs Historic Market, 2012-2016; 11.4.2. Germany Cardiovascular Drugs Forecast Market, 2016-2020; 11.4.3. Germany Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 11.4.4 Germany Cardiovascular Drugs Percentage Of GDP, 2012-2020; 11.4.5 Germany Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020; 11.5 France Cardiovascular Drugs Market; 11.5.1 France Cardiovascular Drugs Historic Market, 2012-2016; 11.5.2 France Cardiovascular Drugs Forecast Market, 2016-2020; 11.5.3 France Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 11.5.4 France Cardiovascular Drugs Percentage Of GDP, 2012-2020; 11.5.5 France Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020; 11.6. Italy Cardiovascular Drugs Market; 11.6.1. Italy Cardiovascular Drugs Historic Market, 2012-2016; 11.6.2. Italy Cardiovascular Drugs Forecast Market, 2016-2020; 11.6.3. Italy Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 11.6.4. Italy Cardiovascular Drugs Percentage Of GDP, 2012-2020; 11.6.5. Italy Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020; 11.7. Spain Cardiovascular Drugs Market; 11.7.1. Spain Cardiovascular Drugs Historic Market, 2012-2016; 11.7.2. Spain Cardiovascular Drugs Forecast Market, 2016-2020; 11.7.3. Spain Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 11.7.4. Spain Cardiovascular Drugs Percentage Of GDP, 2012-2020; 11.7.5. Spain Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020;

12. Eastern Europe Cardiovascular Drugs Market;

12.1.1. Eastern Europe Cardiovascular Drugs Market Overview; 12.1.2. Eastern Europe Cardiovascular Drugs Historic Market, 2012-2016; 12.1.3. Eastern Europe Cardiovascular Drugs Forecast Market, 2016-2020; 12.1.4 Eastern Europe Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 12.2. Eastern Europe Cardiovascular Drugs Market: Country Analysis; 12.3. Russia Cardiovascular Drugs Market; 12.3.1. Russia Cardiovascular Drugs Historic Market, 2012-2016; 12.3.2. Russia Cardiovascular Drugs Forecast Market, 2016-2020; 12.3.3. Russia Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 12.3.4. Russia Cardiovascular Drugs Percentage Of GDP, 2012-2020; 12.3.5. Russia Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020;

13. North America Cardiovascular Drugs Market;

13.1.1. North America Cardiovascular Drugs Market Overview; 13.1.2. North America Cardiovascular Drugs Historic Market, 2012-2016; 13.1.3. North America Cardiovascular Drugs Forecast Market, 2016-2020; 13.1.4. North America Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 13.2. North America Cardiovascular Drugs Market: Country Analysis; 13.3. USA Cardiovascular Drugs Market; 13.3.1. USA Cardiovascular Drugs Historic Market, 2012-2016; 13.3.2. USA Cardiovascular Drugs Forecast Market, 2016-2020; 13.3.3 USA Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 13.3.4. USA Cardiovascular Drugs Percentage Of GDP, 2012-2020; 13.3.5. USA Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020;

14. South America Cardiovascular Drugs Market;

14.1.1. South America Cardiovascular Drugs Market Overview; 14.1.2. South America Cardiovascular Drugs Historic Market, 2012-2016; 14.1.3. South America Cardiovascular Drugs Forecast Market, 2016-2020; 14.1.4. South America Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 14.2. South America Cardiovascular Drugs Market: Country Analysis; 14.3. Brazil Cardiovascular Drugs Market; 14.3.1. Brazil Cardiovascular Drugs Historic Market, 2012-2016; 14.3.2. Brazil Cardiovascular Drugs Forecast Market, 2016-2020; 14.3.3. Brazil Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs); 14.3.4. Brazil Cardiovascular Drugs Percentage Of GDP, 2012-2020; 14.3.5. Brazil Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020;

15. Middle East Cardiovascular Drugs Market;

15.1.1. Middle East Cardiovascular Drugs Market Overview; 15.1.2. Middle East Cardiovascular Drugs Historic Market, 2012-2016; 15.1.3. Middle East Cardiovascular Drugs Forecast Market, 2016-2020; 15.1.4. Middle East Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs);

16. Africa Cardiovascular Drugs Market;

16.1.1. Africa Cardiovascular Drugs Market Overview; 16.1.1. Africa Cardiovascular Drugs Market Overview; 16.1.2. Africa Cardiovascular Drugs Historic Market, 2012-2016; 16.1.3. Africa Cardiovascular Drugs Forecast Market, 2016-2020; 16.1.4. Africa Cardiovascular Drugs Market, 2016, By Segment; Anti-Hypertensive Drugs; Hypolipidemics; Anti Thrombotics; Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs);

17. Cardiovascular Drugs Market Competitive Landscape;

17.1. Company Profiles; 17.2. Bristol-Myers Squibb Company; 17.2.1. Overview; 17.2.2. Products And Services; 17.2.3. Strategy; 17.2.4. Financial Performance; 17.3. Abbott Laboratories Inc.; 17.3.1. Overview; 17.3.2. Products And Services; 17.3.3. Strategy; 17.3.4. Financial Performance; 17.4. Astrazeneca Plc; 17.4.1. Overview; 17.4.2. Products And Services; 17.4.3. Strategy; 17.4.4. Financial Performance; 17.5. Bayer Ag; 17.5.1. Overview; 17.5.2. Products And Services; 17.5.3. Strategy; 17.5.4. Financial Performance; 17.6. Novartis Ag; 17.6.1. Overview; 17.6.2. Products And Services; 17.6.3. Strategy; 17.6.4. Financial Performance;

18. Key Mergers And Acquisitions In The Cardiovascular Drugs Market;

19. Market Background: Pharmaceutical Drugs Market;

19.1.1. Pharmaceutical Drugs Market Characteristics; 19.1.2. Pharmaceutical Drugs Market Historic Growth; 19.1.2.1. Drivers Of The Market; 19.1.2.2. Restraints Of The Market; 19.1.3. Pharmaceutical Drugs Market Forecast Growth; 19.1.3.1. Drivers Of The Market; 19.1.3.2. Restraints Of The Market; 19.1.4. Pharmaceutical Drugs Trends And Strategies; 19.2. Pharmaceutical Drugs Market Regional And Country Analysis; 19.2.1. Global Pharmaceutical Drugs Market, 2016, By Region; 19.2.2. Global Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Region; 19.2.3. Pharmaceutical Drugs Market, 2016, By Country; 19.2.4. Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Country; 19.2.5 Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment; 19.2.6. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment

19.3. Global Pharmaceutical Drugs Market Comparison With Macro Economic Factors; 19.3.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, Global; 19.3.2. Per Capita Average Pharmaceutical Drugs Expenditure, Global; 19.4. Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries; 19.4.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country; 19.4.2. Per Capita Average Pharmaceutical Drugs Expenditure, By Country; 19.5. Key Mergers And Acquisitions In The Pharmaceutical Drugs Market;

20. Pharmaceuticals Industry Financial Margins;

21. Appendix;

21.1. NAICS Definitions Of Industry Covered In This Report; 21.2. Abbreviations; 21.3. Currencies; 21.4. Research Inquiries; 21.5. The Business Research Company; 21.6. Copyright And Disclaimer

Table 1: Global Cardiovascular Drugs Historic Market Growth

Table 2: Global Cardiovascular Drugs Forecast Market Growth

Table 3: Cardiovascular Drugs Market Segmentation

Table 4: Global Cardiovascular Drugs Market, 2016, By Segment

Table 5: Global Cardiovascular Drugs Market, 2012-2020, Historic And Forecast, By Segment

Table 6: Global Cardiovascular Drugs Market, 2016, By Region

Table 7: Global Cardiovascular Drugs Market, 2012-2020, Historic And Forecast, By Region

Table 8: Cardiovascular Drugs Market, 2016, By Country

Table 9: Cardiovascular Drugs Market, 2012-2020, Historic And Forecast, By Country

Table 10: Global Pharmaceutical Market Segments, 2016, By Region

Table 11: Global Pharmaceutical Drugs Market Segments, 2016, By Region

Table 12: Global Pharmaceutical Market Segments, 2016, By Country

Table 13: Global Pharmaceutical Drugs Market Segments, 2016, By Country

Table 14: Cardiovascular Drugs Market Size, Percentage Of GDP, Global

Table 15: Per Capita Average Cardiovascular Drugs Expenditure, Global

Table 16: Cardiovascular Drugs Market Comparison With Macro Economic Factors Across Countries

Table 17: Cardiovascular Drugs Market Size, Percentage Of GDP, By Country

Table 18: Per Capita Average Cardiovascular Drugs Expenditure, By Country

Table 19: Global Number Of Pharmacists, 2016, By Country

Table 20: Global Cardiovascular Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country

Table 21: Global Number Of Pharma Enterprises, 2016, By Country

Table 22: Global Cardiovascular Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country

Table 23: Global Average Spending On R&D/Product Development, 2016, By Country

Table 24: Global Cardiovascular Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country

Table 25: Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Table 26: Global Cardiovascular Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Table 27: Prevalent Cases Of Hypertension, 2014, By Country

Table 28: Prevalent Cases Of Parkinsons Disease, 2014, By Country

Table 29: Global Number Of General Practitioners 2016, By Country

Table 30: Global Cardiovascular Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country

Table 31: Asia-Pacific Cardiovascular Drugs Historic Market, 2012-2016

Table 32: Asia-Pacific Cardiovascular Drugs Forecast Market, 2016-2020

Table 33: Asia-Pacific Cardiovascular Drugs Market, 2016, By Segment

Table 34: China Cardiovascular Drugs Historic Market, 2012-2016

Table 35: China Cardiovascular Drugs Forecast Market, 2016-2020

Table 36: China Cardiovascular Drugs Market, 2016, By Segment

Table 37: China Cardiovascular Drugs Percentage Of GDP, 2012-2020

Table 38: China Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020

Table 39: India Cardiovascular Drugs Historic Market, 2012-2016

Table 40: India Cardiovascular Drugs Forecast Market, 2016-2020

Table 41: India Cardiovascular Drugs Market, 2016, By Segment

Table 42: India Cardiovascular Drugs Percentage Of GDP, 2012-2020

Table 43: India Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020

Table 44: Japan Cardiovascular Drugs Historic Market, 2012-2016

Table 45: Japan Cardiovascular Drugs Forecast Market, 2016-2020

Table 46: Japan Cardiovascular Drugs Market, 2016, By Segment

Table 47: Japan Cardiovascular Drugs Percentage Of GDP, 2012-2020

Table 48: Japan Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020

Table 49: Australia Cardiovascular Drugs Historic Market, 2012-2016

Table 50: Australia Cardiovascular Drugs Forecast Market, 2016-2020

Table 51: Australia Cardiovascular Drugs Market, 2016, By Segment

Table 52: Australia Cardiovascular Drugs Percentage Of GDP, 2012-2020

Table 53: Australia Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020

Table 54: Western Europe Cardiovascular Drugs Historic Market, 2012-2016

Table 55: Western Europe Cardiovascular Drugs Forecast Market, 2016-2020

Table 56: Western Europe Cardiovascular Drugs Market, 2016, By Segment

Table 57: UK Cardiovascular Drugs Historic Market, 2012-2016

Table 58: UK Cardiovascular Drugs Forecast Market, 2016-2020

Table 59: UK Cardiovascular Drugs Market, 2016, By Segment

Table 60: UK Cardiovascular Drugs Percentage Of GDP, 2012-2020

Table 61: UK Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020

Table 62: Germany Cardiovascular Drugs Historic Market, 2012-2016

Table 63: Germany Cardiovascular Drugs Forecast Market, 2016-2020

Table 64: Germany Cardiovascular Drugs Market, 2016, By Segment

Table 65: Germany Cardiovascular Drugs Percentage Of GDP, 2012-2020

Table 66: Germany Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020

Table 67: France Cardiovascular Drugs Historic Market, 2012-2016

Table 68: France Cardiovascular Drugs Forecast Market, 2016-2020

Table 69: France Cardiovascular Drugs Market, 2016, By Segment

Table 70: France Cardiovascular Drugs Percentage Of GDP, 2012-2020

Table 71: France Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020

Table 72: Italy Cardiovascular Drugs Historic Market, 2012-2016

Table 73: Italy Cardiovascular Drugs Forecast Market, 2016-2020

Table 74: Italy Cardiovascular Drugs Market, 2016, By Segment

Table 75: Italy Cardiovascular Drugs Percentage Of GDP, 2012-2020

Table 76: Italy Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020

Table 77: Spain Cardiovascular Drugs Historic Market, 2012-2016

Table 78: Spain Cardiovascular Drugs Forecast Market, 2016-2020

Table 79: Spain Cardiovascular Drugs Market, 2016, By Segment

Table 80: Spain Cardiovascular Drugs Percentage Of GDP, 2012-2020

Table 81: Spain Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020

Table 82: Eastern Europe Cardiovascular Drugs Historic Market, 2012-2016

Table 83: Eastern Europe Cardiovascular Drugs Forecast Market, 2016-2020

Table 84: Eastern Europe Cardiovascular Drugs Market, 2016, By Segment

Table 85: Russia Cardiovascular Drugs Historic Market, 2012-2016

Table 86: Russia Cardiovascular Drugs Forecast Market, 2016-2020

Table 87: Russia Cardiovascular Drugs Market, 2016, By Segment

Table 88: Russia Cardiovascular Drugs Percentage Of GDP, 2012-2020

Table 89: Russia Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020

Table 90: North America Cardiovascular Drugs Historic Market, 2012-2016

Table 91: North America Cardiovascular Drugs Forecast Market, 2016-2020

Table 92: North America Cardiovascular Drugs Market, 2016, By Segment

Table 93: USA Cardiovascular Drugs Historic Market, 2012-2016

Table 94: USA Cardiovascular Drugs Forecast Market, 2016-2020

Table 95: USA Cardiovascular Drugs Market, 2016, By Segment

Table 96: USA Cardiovascular Drugs Percentage Of GDP, 2012-2020

Table 97: USA Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020

Table 98: South America Cardiovascular Drugs Historic Market, 2012-2016

Table 99: South America Cardiovascular Drugs Forecast Market, 2016-2020

Table 100: South America Cardiovascular Drugs Market, 2016, By Segment

Table 101: Brazil Cardiovascular Drugs Historic Market, 2012-2016

Table 102: Brazil Cardiovascular Drugs Forecast Market, 2016-2020

Table 103: Brazil Cardiovascular Drugs Market, 2016, By Segment

Table 104: Brazil Cardiovascular Drugs Percentage Of GDP, 2012-2020

Table 105: Brazil Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020

Table 106: Middle East Cardiovascular Drugs Historic Market, 2012-2016

Table 107: Middle East Cardiovascular Drugs Forecast Market, 2016-2020

Table 108: Middle East Cardiovascular Drugs Market, 2016, By Segment

Table 109: Africa Cardiovascular Drugs Historic Market, 2012-2016

Table 110: Africa Cardiovascular Drugs Forecast Market, 2016-2020

Table 111: Africa Cardiovascular Drugs Market, 2016, By Segment

Table 112: Bristol-Myers Squibb Company Financial Performance

Table 113: Abbott Laboratories Inc. Financial Performance

Table 114: Astrazeneca Plc Financial Performance

Table 115: Bayer AG Financial Performance

Table 116: Novartis AG Financial Performance

Table 117: Pharmaceutical Drugs Market Historic Growth

Table 118: Pharmaceutical Drugs Market Forecast Growth

Table 119: Global Pharmaceutical Drugs Market, 2016, By Region

Table 120: Global Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Region

Table 121: Pharmaceutical Drugs Market, 2016, By Country

Table 122: Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Country

Table 123: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment

Table 124: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment

Table 125: Pharmaceutical Drugs Market Size, Percentage Of GDP, Global

Table 126: Per Capita Average Pharmaceutical Drugs Expenditure, Global

Table 127: Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries

Table 128: Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country

Table 129: Per Capita Average Pharmaceutical Drugs Expenditure, By Country

Table 130: Pharmaceuticals Industry Financial Margins

Figure 1: Global Cardiovascular Drugs Historic Market Growth

Figure 2: Global Cardiovascular Drugs Forecast Market Growth

Figure 3: Cardiovascular Drugs Market Segmentation

Figure 4: Global Cardiovascular Drugs Market, 2016, By Segment

Figure 5: Global Cardiovascular Drugs Market, 2012-2020, Historic And Forecast, By Segment

Figure 6: Global Cardiovascular Drugs Market, 2016, By Region

Figure 7: Global Cardiovascular Drugs Market, 2012-2020, Historic And Forecast, By Region

Figure 8: Cardiovascular Drugs Market, 2016, By Country

Figure 9: Cardiovascular Drugs Market, 2012-2020, Historic And Forecast, By Country

Figure 10: Global Pharmaceutical Market Segments, 2016, By Region

Figure 11: Global Pharmaceutical Drugs Market Segments, 2016, By Region

Figure 12: Global Pharmaceutical Market Segments, 2016, By Country

Figure 13: Global Pharmaceutical Drugs Market Segments, 2016, By Country

Figure 14: Cardiovascular Drugs Market Size, Percentage Of GDP, Global

Figure 15: Per Capita Average Cardiovascular Drugs Expenditure, Global

Figure 16: Cardiovascular Drugs Market Comparison With Macro Economic Factors Across Countries

Figure 17: Cardiovascular Drugs Market Size, Percentage Of GDP, By Country

Figure 18: Per Capita Average Cardiovascular Drugs Expenditure, By Country

Figure 19: Global Number Of Pharmacists, 2016, By Country

Figure 20: Global Cardiovascular Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country

Figure 21: Global Number Of Pharma Enterprises, 2016, By Country

Figure 22: Global Cardiovascular Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country

Figure 23: Global Average Spending On R&D/Product Development, 2016, By Country

Figure 24: Global Cardiovascular Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country

Figure 25: Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Figure 26: Global Cardiovascular Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Figure 27: Prevalent Cases Of Hypertension, 2014, By Country

Figure 28: Prevalent Cases Of Parkinsons Disease, 2014, By Country

Figure 29: Global Number Of General Practitioners 2016, By Country

Figure 30: Global Cardiovascular Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country

Figure 31: Asia-Pacific Cardiovascular Drugs Historic Market, 2012-2016

Figure 32: Asia-Pacific Cardiovascular Drugs Forecast Market, 2016-2020

Figure 33: Asia-Pacific Cardiovascular Drugs Market, 2016, By Segment

Figure 34: China Cardiovascular Drugs Historic Market, 2012-2016

Figure 35: China Cardiovascular Drugs Forecast Market, 2016-2020

Figure 36: China Cardiovascular Drugs Market, 2016, By Segment

Figure 37: China Cardiovascular Drugs Percentage Of GDP, 2012-2020

Figure 38: China Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020

Figure 39: India Cardiovascular Drugs Historic Market, 2012-2016

Figure 40: India Cardiovascular Drugs Forecast Market, 2016-2020

Figure 41: India Cardiovascular Drugs Market, 2016, By Segment

Figure 42: India Cardiovascular Drugs Percentage Of GDP, 2012-2020

Figure 43: India Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020

Figure 44: Japan Cardiovascular Drugs Historic Market, 2012-2016

Figure 45: Japan Cardiovascular Drugs Forecast Market, 2016-2020

Figure 46: Japan Cardiovascular Drugs Market, 2016, By Segment

Figure 47: Japan Cardiovascular Drugs Percentage Of GDP, 2012-2020

Figure 48: Japan Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020

Figure 49: Australia Cardiovascular Drugs Historic Market, 2012-2016

Figure 50: Australia Cardiovascular Drugs Forecast Market, 2016-2020

Figure 51: Australia Cardiovascular Drugs Market, 2016, By Segment

Figure 52: Australia Cardiovascular Drugs Percentage Of GDP, 2012-2020

Figure 53: Australia Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020

Figure 54: Western Europe Cardiovascular Drugs Historic Market, 2012-2016

Figure 55: Western Europe Cardiovascular Drugs Forecast Market, 2016-2020

Figure 56: Western Europe Cardiovascular Drugs Market, 2016, By Segment

Figure 57: UK Cardiovascular Drugs Historic Market, 2012-2016

Figure 58: UK Cardiovascular Drugs Forecast Market, 2016-2020

Figure 59: UK Cardiovascular Drugs Market, 2016, By Segment

Figure 60: UK Cardiovascular Drugs Percentage Of GDP, 2012-2020

Figure 61: UK Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020

Figure 62: Germany Cardiovascular Drugs Historic Market, 2012-2016

Figure 63: Germany Cardiovascular Drugs Forecast Market, 2016-2020

Figure 64: Germany Cardiovascular Drugs Market, 2016, By Segment

Figure 65: Germany Cardiovascular Drugs Percentage Of GDP, 2012-2020

Figure 66: Germany Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020

Figure 67: France Cardiovascular Drugs Historic Market, 2012-2016

Figure 68: France Cardiovascular Drugs Forecast Market, 2016-2020

Figure 69: France Cardiovascular Drugs Market, 2016, By Segment

Figure 70: France Cardiovascular Drugs Percentage Of GDP, 2012-2020

Figure 71: France Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020

Figure 72: Italy Cardiovascular Drugs Historic Market, 2012-2016

Figure 73: Italy Cardiovascular Drugs Forecast Market, 2016-2020

Figure 74: Italy Cardiovascular Drugs Market, 2016, By Segment

Figure 75: Italy Cardiovascular Drugs Percentage Of GDP, 2012-2020

Figure 76: Italy Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020

Figure 77: Spain Cardiovascular Drugs Historic Market, 2012-2016

Figure 78: Spain Cardiovascular Drugs Forecast Market, 2016-2020

Figure 79: Spain Cardiovascular Drugs Market, 2016, By Segment

Figure 80: Spain Cardiovascular Drugs Percentage Of GDP, 2012-2020

Figure 81: Spain Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020

Figure 82: Eastern Europe Cardiovascular Drugs Historic Market, 2012-2016

Figure 83: Eastern Europe Cardiovascular Drugs Forecast Market, 2016-2020

Figure 84: Eastern Europe Cardiovascular Drugs Market, 2016, By Segment

Figure 85: Russia Cardiovascular Drugs Historic Market, 2012-2016

Figure 86: Russia Cardiovascular Drugs Forecast Market, 2016-2020

Figure 87: Russia Cardiovascular Drugs Market, 2016, By Segment

Figure 88: Russia Cardiovascular Drugs Percentage Of GDP, 2012-2020

Figure 89: Russia Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020

Figure 90: North America Cardiovascular Drugs Historic Market, 2012-2016

Figure 91: North America Cardiovascular Drugs Forecast Market, 2016-2020

Figure 92: North America Cardiovascular Drugs Market, 2016, By Segment

Figure 93: USA Cardiovascular Drugs Historic Market, 2012-2016

Figure 94: USA Cardiovascular Drugs Forecast Market, 2016-2020

Figure 95: USA Cardiovascular Drugs Market, 2016, By Segment

Figure 96: USA Cardiovascular Drugs Percentage Of GDP, 2012-2020

Figure 97: USA Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020

Figure 98: South America Cardiovascular Drugs Historic Market, 2012-2016

Figure 99: South America Cardiovascular Drugs Forecast Market, 2016-2020

Figure 100: South America Cardiovascular Drugs Market, 2016, By Segment

Figure 101: Brazil Cardiovascular Drugs Historic Market, 2012-2016

Figure 102: Brazil Cardiovascular Drugs Forecast Market, 2016-2020

Figure 103: Brazil Cardiovascular Drugs Market, 2016, By Segment

Figure 104: Brazil Cardiovascular Drugs Percentage Of GDP, 2012-2020

Figure 105: Brazil Per Capita Average Cardiovascular Drugs Expenditure, 2012-2020

Figure 106: Middle East Cardiovascular Drugs Historic Market, 2012-2016

Figure 107: Middle East Cardiovascular Drugs Forecast Market, 2016-2020

Figure 108: Middle East Cardiovascular Drugs Market, 2016, By Segment

Figure 109: Africa Cardiovascular Drugs Historic Market, 2012-2016

Figure 110: Africa Cardiovascular Drugs Forecast Market, 2016-2020

Figure 111: Africa Cardiovascular Drugs Market, 2016, By Segment

Figure 112: Bristol-Myers Squibb Company Financial Performance

Figure 113: Abbott Laboratories Inc. Financial Performance

Figure 114: Astrazeneca Plc Financial Performance

Figure 115: Bayer AG Financial Performance

Figure 116: Novartis AG Financial Performance

Figure 117: Pharmaceutical Drugs Market Historic Growth

Figure 118: Pharmaceutical Drugs Market Forecast Growth

Figure 119: Global Pharmaceutical Drugs Market, 2016, By Region

Figure 120: Global Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Region

Figure 121: Pharmaceutical Drugs Market, 2016, By Country

Figure 122: Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Country

Figure 123: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment

Figure 124: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment

Figure 125: Pharmaceutical Drugs Market Size, Percentage Of GDP, Global

Figure 126: Per Capita Average Pharmaceutical Drugs Expenditure, Global

Figure 127: Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries

Figure 128: Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country

Figure 129: Per Capita Average Pharmaceutical Drugs Expenditure, By Country

Figure 130: Pharmaceuticals Industry Financial Margins

  • Single User License (for access by one person)
  • Site License (for access of one office location of a company)
  • Corporate License (allow access by all staff of the company)
To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Bristol-Myers Squibb Company, Abbott Laboratories Inc., AstraZeneca PLC, Bayer AG, and Novartis AG

Anti-Hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrythmic And Anti-Anginal Drugs)

select a license
Single User License
USD 4000 INR 276000
Hard Copy License
USD 4000 INR 276000
CD-Rom
USD 4000 INR 276000
Site License
USD 6000 INR 414000
Corporate User License
USD 8000 INR 552000

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com